Nvest Financial LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Nvest Financial LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 2,576 shares of the medical device company’s stock, valued at approximately $200,000.

A number of other hedge funds have also modified their holdings of DXCM. Blue Whale Capital LLP boosted its position in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after purchasing an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC raised its stake in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom during the 3rd quarter valued at about $683,000. National Pension Service grew its stake in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new position in DexCom in the third quarter worth approximately $650,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Citigroup lifted their price objective on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Royal Bank of Canada lowered their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

DexCom Stock Performance

NASDAQ DXCM opened at $88.30 on Wednesday. The company’s fifty day moving average is $79.73 and its two-hundred day moving average is $76.70. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a market capitalization of $34.49 billion, a price-to-earnings ratio of 52.87, a P/E/G ratio of 2.23 and a beta of 1.12.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.30% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.